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Selection of dose for cancer patients treated with radiation therapy (RT) must balance the increased efficacy with
the increased toxicity associated with higher dose. Historically, a single dose has been selected for a population
of patients (e.g., all stage III non-small cell lung cancer). However, the availability of new biologic markers for
toxicity and efficacy allows the possibility of selecting a more personalized dose. We consider the use of statistical
models for toxicity and efficacy as a function of RT dose and biomarkers to select an optimal dose for an
individual patient, defined as the dose that maximizes the probability of efficacy minus the sum of weighted
toxicity probabilities. This function can be shown to be equal to the expected value of the utility derived from a
particular family of bivariate outcome utility matrices. We show that if dose is linearly related to the probability
of toxicity and efficacy, then any marker that only acts additively with dose cannot improve efficacy, without
also increasing toxicity. Using a dataset of lung cancer patients treated with RT, we illustrate this approach
and compare it to non-marker-based dose selection. Because typical metrics used in evaluating new markers
(e.g., area under the ROC curve) do not directly address the ability of a marker to improve efficacy at a fixed
probability of toxicity, we utilize a simulation study to assess the effects of marker-based dose selection on toxicity
and efficacy outcomes. Copyright © 2014 John Wiley & Sons, Ltd.
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1. Introduction
The dose of radiation therapy (RT) used in clinical practice is typically fixed for a given type of cancer
and does not vary across subjects. Recommended dose values are either based on historical practice
and retrospective toxicity analysis or a formal phase I trial in which radiation dose to the tumor was
escalated until it corresponded to a target probability of toxicity [1]. However, it is recognized that there
is variability between patients in their sensitivity to radiation. Various biomarkers of this sensitivity have
been proposed. These include biologic markers [2], genetic markers [3–5], and standard clinical factors
(e.g., smoking as protective for lung toxicity). Some of thesemarkers aremeasured at baseline (prior to RT
start) while others are measured mid-treatment, that is, measured after RT starts but prior to completion
of RT. We have hypothesized that mid-treatment markers that measure change in response to a moderate
dose of RT will be most predictive of an individual’s sensitivity to RT. Regardless of the type and timing
(assuming it is prior to completion of treatment), the availability of these markers makes possible a more
personalized dose selection.
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While dose selection is often the intended use, clinical papers on new markers typically focus on
measures of the marker’s discriminatory ability, such as area under the curve (AUC), which, as we will
show, do not directly address the usefulness of the marker for dose selection purposes. When these
papers do discuss how the markers might be used for dose selection, they generally do so only on
the basis of toxicity, partly because dose selection in RT has historically been limited to giving the
highest dose possible subject to toxicity considerations. There have, however, been a few approaches,
which explicitly incorporated efficacy considerations in addition to toxicity. One of the earliest was
based on the concept of uncomplicated control defined as local tumor control (at a defined timepoint)
and no serious complications [6, 7]. One weakness of such an approach is the implicit assumption
that toxicity and tumor progression are equally undesirable, an assumption that is seldom reasonable
and avoided in our proposed utility-based approach. Also, in contrast to our proposed approach, the
notion of uncomplicated control does not allow incorporation of multiple toxicities of varying type
and severity. Recently, Jang et al. proposed ‘Quality-Adjusted Time Without Symptoms or Toxicity’
or Q-TWiST, as a single metric with which to compare treatments based on combined efficacy and
toxicity endpoints [8]. Q-TWiST was defined as a weighted linear combination of the time spent in
various health states. This is an appealing approach but requires detailed patient data on the duration
of toxicity.
In this paper, we focus on how to use expanded toxicity models, in conjunction with efficacy
models, to select a dose of RT that is optimal for an individual patient. To simplify calculations, we
focus on the estimated survival value at a fixed timepoint as our efficacy endpoint. We also focus on the
binary toxicity case but show howmultiple binary or ordinal toxicity variables could be utilized. The first
approach we consider, called the ‘isotoxic’ approach, selects a dose that corresponds to an acceptable
probability of toxicity for a given patient. The second approach, which we call the ‘utility’ approach,
combines the toxicity model and the efficacy model via a ‘utility’ function [9] given by the probabil-
ity of efficacy minus the weighted sum of the probability of various toxicities and selects the dose that
maximizes this utility for an individual patient. Using a database of lung cancer patients treated with RT,
we build several models for toxicity and efficacy as a function of dose and various markers and use a
simulation to illustrate these approaches.
An important consideration when working with RT dose is that RT is distinct from chemotherapy
and most other drug settings in that the dose to the tumor is typically different from the dose to the
surrounding normal tissue or organ. In a typical treatment plan, a series of radiation beams (typically two
to nine), each entering the body at a different location, are targeted at the tumor site. In 3D conformal
RT, each beam may be shaped, and the dose of radiation may vary in a linear fashion across the beam.
A newer technique, Intensity Modulated RT, splits each beam into a grid of ‘beamlets’, and the dose
of each beamlet can be independently controlled [10]. Although the tumor is the focal point and thus
receives the highest dose of radiation, all of the normal tissue in the path of one or more beams also
receives some dose of radiation. Taking lung cancer as an example, it is the dose to the tumor (often
referred to as the prescription dose) that drives local tumor control, whereas it is the dose to the normal
lung tissue (often calculated as mean dose to normal lung tissue) that drives lung toxicity. For a given
patient, higher tumor dose generally implies higher mean lung dose. However, because of heterogeneity
in tumor size and location, the correlation between tumor dose and mean lung dose, across patients, is
often weak.
A RT treatment plan consists of the location and daily (per ‘fraction’) dose associated with a series of
beams along with plan for timing and number of fractions. Specification of a full treatment plan requires
choice of number of beams, direction of each beam, and dose for each beamlet within a beam. In this
paper, we more narrowly focus on the choice of a single number (tumor dose D or normal tissue dose d)
that in turn fully prescribes the treatment plan. In practice, this means that we assume the fractionation
scheme, the location of beams, and the relative intensity of each beam are all fixed. This ‘plan’ can then
be scaled up or down, but, importantly, the ratio of D/d is fixed. Throughout the paper, we will use ‘r’
to denote the ratio D/d.While r will vary across subjects, its value can easily be calculated for a given
patient/plan combination. In the Simulation Study section, we calculate the observed r for each patient,
based on the actual treatment plan they were treated with. For prospective use, one could come up with an
initial treatment plan to deliver a tumor dose at the high end of possible values and then use the observed
r associated with that plan when selecting the final dose (which would just scale down or less likely up
the initial plan).
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2. Methods
2.1. Notation
Let Di denote tumor dose, di denote dose to normal tissue, ri the ratio Di∕di, and Ti and Ei, respectively,








, for patient i.
We assume availability of models 𝜋Ti = f
−1(di,Mi, 𝛽) and 𝜋Ei = g
−1(Di,Gi, 𝛼), where M and G denote
scalars or vectors of marker values, 𝛽 and 𝛼 are parameter vectors, and f () and g() are link functions.
2.2. Dose selection strategies
We describe two methods for incorporating toxicity and efficacy markers in dose selection. The first is
based on the expanded model for toxicity as a function of M and d and solves 𝜋Ti = p
∗ = f −1(di,Mi, 𝛽)
for di,where p
∗ is a target probability of toxicity. Note that the assumption of a fixed r, which implies the
selection of either D or d, uniquely defines the treatment plan. If no markers for toxicity are available,
this approach reduces to selection of the normal tissue dose corresponding to the target rate of toxicity.
We refer to this as the ‘isotoxic’ approach because it treats every patient at the same estimated probability
of toxicity and ignores the dose-efficacy model.
A second approach, and one which we view as preferable, combines the models for T and E and selects
the dose, which maximizes the utility function U():
U(di, ri,Mi,Gi) = P
(
Ei = 1 |Di = ri ∗ di,Gi) − 𝜃 ∗ P (Ti = 1 | di,Mi) (1)
Note that Dican be replaced with ri*di so that Eq. (1) is a function of only a single dose term, di. In many
instances, there are multiple types of toxicity. For example, in lung cancer, esophageal and heart toxicity
are also of concern and are commonly considered in treatment planning. The expression in Eq. (1) is then
easily generalized to
U(di, ri,Mi,Gi) = P
(
Ei = 1 |Di = ri ∗ di,Gi) −∑j 𝜃j ∗ P (Tij = 1 | dij,Mi) (2)
where normal tissue or organ is indexed by j. We refer to this as the ‘utility’ approach. The last term in
Eq. (2) is similar to several recently proposed metrics for phase I trials, including ‘total toxicity burden’
[11]. We note that in both approaches, additional covariates such as smoking status or baseline lung
function could also be included in the model for toxicity. In practice, use of this approach requires one
to choose a value for 𝜃. This value could be elicited from clinicians, or it could be selected by individual
patients. All else being equal, as 𝜃 increases, Eq. (1) will be maximized by smaller d. Thus, 𝜃 could also
be viewed as a tuning parameter, with its value chosen to result in an acceptable marginal rate of toxicity
for a population of patients, calculated as
P(T = 1) = 1∕n
∑
i
P(Ti = 1| d̂i (𝜃, ri,Mi))
where d̂i maximizes Eq. (1) and is thus a function of 𝜃, ri, and Mi. We note that maximizing∑
i Ui(di, ri,Mi) over di and choosing the value of 𝜃 such that P(T = 1) = p∗ is analogous to a Lagrange
multiplier approach. The utility function approach is more general than the isotoxic approach, because
the isotoxic approach forces P(Ti = 1) = p∗ for all i, whereas the utility function method only forces the
average of P(Ti = 1) to equal p∗.
In addition to controlling the average rate of toxicity in the utility function approach, it may be desirable
to also limit an individual patient’s probability of toxicity. This can be accomplished by incorporating an
additional individual level constraint in themaximization ofU(di). For example, di < dmax orP(Ti = 1) < c.
The latter approach has been used in dose finding designs to determine the set of ‘acceptable’ doses from
which an optimal dose is then selected on the basis of toxicity and efficacy considerations [12].
Efficacy and the efficacy/toxicity trade-off are increasingly being considered in dose finding trial
designs [13]. We describe two specific examples here and note the similarity to the utility approach
described earlier. The first is a proposed dose finding trial design based on bivariate toxicity and efficacy
outcomes [14]. Briefly, their method assumes ordinal toxicity and efficacy outcomes and the utility (or
desirability) associated with each possible bivariate outcome, which is elicited from the clinician. An
example for binary toxicity and efficacy is given in the matrix in the succeeding text.
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Given models for T and E as a function of dose, one can calculate the expected utility for any dose
value by a weighted sum as
E (U|d, r,M,G) =∑
j,k
Ujk ∗ P(E = j,T = k|d, r,M,G)
If we assume that, conditional on dose and marker values, T and E are independent, a little algebra shows




The authors in [14] fixed U1 = 100 and U01 = 0, with the interior values set by clinicians. If both
E and T are binary, this allows choice of two values. Use of Eq. (1) reduces this to choice of a single
parameter by forcing U10 − U00 = U11 − U01 , that is, the increase in utility or benefit associated with
positive efficacy is the same regardless of whether toxicity is experienced or not.
A second example of dose finding based on both efficacy and toxicity is given in [15], who define the










where 𝜋∗E and 𝜋
∗
T are, respectively, elicited from the clinician as the smallest efficacy rate they would
accept if the treatment was associated with no toxicity and the highest toxicity rate they would accept if
the treatment had 100% efficacy. When p = 1, it can be shown that
c ∗ (1 − x) = 𝜋E − 𝜃 ∗ 𝜋T




. Thus, in the case where p = 1, selecting dose
to maximize (1 − x) from Eq. (3) is equivalent to maximizing Eq. (1).
2.3. Evaluation of potential dose selection markers
Reports on new biomarkers for toxicity or efficacy typically report odds ratios and measures of discrimi-
natory ability such as AUC, with associated p-values from tests of no discriminatory ability or no increase
in AUC relative to a dose alone model. These metrics are useful and relevant if the new marker is to be
used in a purely predictive fashion (e.g., counsel patients regarding risk of toxicity). Often, however, the
goal is to use the new marker to select a dose in such a way that overall outcomes are improved. More
precisely, there is an expectation that marker-based dose selection will result in either (i) increased 𝜋E
at the same 𝜋T or (ii) decreased 𝜋T at the same 𝜋E. However, neither of these events may occur, even
when using a marker that substantially increases AUC over the AUC for dose alone. As an illustration,
consider the hypothetical lung cancer scenario depicted in Figure 1. Suppose a biomarker is discovered,
which enables us to identify two groups of patients: one with a uniformly higher and the other with a
lower risk of toxicity. So rather than predicting toxicity using only mean lung dose (d, solid line), we can
now more accurately predict toxicity using the new biomarker (dashed lines). For simplicity of visual
presentation, assume that there are 100 patients to be treated, all with the same tumor size and location
(so that the ratio d∕D is the same for all patients). Using the dose only toxicity model, we could treat all
patients at a tumor dose of 70 Gy (equivalent to d = 15 Gy), and the toxicity and efficacy rates would be
25% and 60%. With the new biomarker, we could instead treat each patient at their ‘personalized’ dose
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 5330–5339
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Figure 1. Illustration of result that when probabilities of toxicity and efficacy (local control) are linearly related
to dose, a prognostic marker for toxicity cannot be used to improve efficacy without also increasing toxicity.
corresponding to a toxicity probability of 25% (65 or 75 Gy for more or less sensitive patients). With this
approach, the overall toxicity rate is still 25%, but the overall efficacy rate is now the average of 55%
(for patients treated at 65 Gy) and 65% (for patients treated at 75 Gy), equal to 60%, which is the same
as that achieved by ignoring the biomarker. To see that this result also holds in the more realistic setting
where r varies across patients, suppose
P
(
Ei = 1|Di = ridi) = 𝛼0 + 𝛼1ridi
and
P[Ti = 1|di,Mi] = 𝛽01I(Mi = 1) + 𝛽02I(Mi = 2) + 𝛽1di
where M denotes marker group 1 or 2, which are of the same size so that P(Mi = 1) = P(Mi = 2) = 0.5
(although this is not necessary for the result to hold). Then, the probability of toxicity conditional only
on dose is given by
P
(
di|Ti = 1) = 𝛽0 + 𝛽1di
where 𝛽0 = .5 ∗ (𝛽01 + 𝛽02)
We can calculate the marginal (across the population of patients) probabilities of T and E following
two different dose selection strategies.
Strategy 1: Treat all patients at d = (p∗ − 𝛽0)∕𝛽1
Strategy 2: If Mi =1, treat at d = (p∗ − 𝛽01)∕𝛽1, else if Mi = 2, treat at di = (p∗ − 𝛽02)∕𝛽1
It is readily seen that under both strategies, the expected population toxicity rate = p∗. Under strategy
1, di is fixed and constant across patients, but ri varies between patients. Thus, the average probability of
efficacy is given by integrating the subject specific probabilities over the distribution of r.















Under strategy 2, d varies across subjects according toM. Similar algebra to the preceding text yields
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Thus, despite the use of a marker that allows better prediction of toxicity, strategy 2 results in the same
marginal probability of efficacy as strategy 1, which is based only on a dose. This result depends on the
linear dose-outcome relationships and the additive effect of the marker. Another crucial assumption is
that there is no interaction between dose and marker. This result would not hold in the presence of an
interaction or when the true relation between the probability of toxicity and dose is not linear.
3. Simulation study
The aforementioned work was motivated by our work with a database of outcomes and biomarkers for
lung cancer patients treated with RT. Using these data, we fit models for efficacy and toxicity as a function
of dose with or without various biomarkers. To illustrate the issues associated with marker-based dose
selection in RT, we conducted a simulation study.
3.1. Toxicity models
The primary dose limiting toxicity for these patients is lung toxicity (pneumonitis grade 2 or higher),
which we model as a function of mean lung dose (d) and cytokine levels measured from blood draws
pre and during RT. Details of five logistic regression toxicity models that fit to these data are given in
Table I. Maximum likelihood was used to estimate model parameters.We use the level of the cytokine IL8
measured at baseline and the cytokines TGF𝛽 and TGF𝛼, each measured mid-treatment. Higher baseline
levels of IL8 appear to be protective, whereas increased values of the other cytokines mid-treatment
appear to increase the risk of toxicity. For illustration purposes, we utilize TGF𝛽 as a continuous predictor
and TGF𝛼 as a binary predictor with values classified as above or below the median. Figure 2 shows the
Table I. Toxicity and efficacy results when dose is selected according to the given model.
Local progression free survival at 2 years (%)
Utility without Utility with
Model Toxicity equation (on logit scale) AUC Isotoxic efficacy markers efficacy markers
1 −5.16 + 0.2 ∗ d 0.72 40.0 44.1 48.4
2 −3.66 + 0.22 ∗ d − 0.85 ∗ log(IL8) 0.78 42.2 45.8 50.2
3 −3.72 + 0.19 ∗ d − 0.79 ∗ log(IL8) 0.83 44.8 47.0 51.0
+0.03 ∗ TGF𝛽 ∗ d
4 −5.34 + 0.17 ∗ d + 0.07 ∗ d ∗ I(TGF𝛼 > 3) 0.76 44.2 45.1 52.1
5* −5.6 + 0.12 ∗ d + 0.16 ∗ d ∗ I(TGF𝛼 > 3) NA 54.0 54.5 57.6
Toxicity rate is equal to 15% in every case.
*Hypothetical model.
Figure 2. Estimated probability of lung toxicity for all patients and by mid-treatment transforming growth factor
alpha (TGFA) levels.
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 5330–5339
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fitted models 1 and 4. Models 3 and 4 have dose * marker interactions with no main effect for marker.
While we have also fit models using these markers as main effects, here we present only the marker * dose
interaction models for illustration purposes. We do not address the very important issues of multiplicity
or model validation. Finally, we note that model 5 is hypothetical and was included merely to illustrate
the effect of a stronger dose * marker interaction.
3.2. Efficacy model
Because RT is a local and not systemic treatment, we utilize local progression free survival (LPFS),
defined as the minimum time to either local progression of the treated tumor or death, as our measure of
efficacy. To estimate the effect of biomarkers and tumor dose on LPFS, we used Cox proportional hazard
models because many patients are censored during the first 2 years. Our goal was to use biomarkers to
identify patients who would (or would not) benefit from higher RT dose. We used a stepwise procedure
in which dose and dose * biomarker interactions were included as potential covariates. For biomark-
ers, we used expression values of 84 miRNAs, which are detectable in serum. In addition to dose, 23
dose * miRNA interactions were jointly significant at the 0.10 level. From the fitted Cox model, we
calculated the dose coefficient for patient i as 𝛼0+
∑
j
𝛼j ∗ Xij, where 𝛼 and 𝛼j denote the parameter coeffi-
cients for dose and the interaction between dose and the jth miRNA term and Xij denotes the value of the
jth miRNA for the ith patient. Although this biomarker could be used in a continuous fashion, we chose
to group patients into two groups for illustration purposes in the simulation study. Patients whose dose
coefficient was in the lowest 1/3 had significantly worse LPFS and no dose effect compared with patients
with higher dose coefficient (Figure 3), so we used these two groups. LPFS at 2 years is a commonly uti-
lized endpoint in RT lung trials, and we use it here as our binary efficacy endpoint and estimate it from
the fitted Cox model as
Ŝ (2 |D,G) = Ŝ0 (2)exp(𝛼1D∗I(G=1)+𝛼2D∗I(G=2))
where Ŝ0 (2) is the Nelson–Aalen estimate of baseline survival at 2 years. Dose had a highly significant
impact on LPFS in group 1 (estimated hazard ratio = 0.90 per 1 Gy increase in tumor dose (p < 0.01)
but not in group 2 (estimated hazard ratio = 0.99, p = 0.78).
3.3. Simulation methods
The simulation (or virtual clinical trial) followed these steps for each of the five toxicity models and each
patient (total of 82) in the database.
(1) If using Isotoxic approach: Calculate the value d corresponding to 15% probability of toxicity. If
di > 25, then set di = 25.
Figure 3. Kaplan–Meier estimates of local progression free survival for groups of patients defined by miRNA
group and dose.
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OR
If using Utility approach: For given 𝜃, calculate di, which maximizes the utility given by Eq. (1),
using either the dose only efficacy model or the dose and miRNA efficacy model, and adjust 𝜃 so
that the population toxicity rate is 0.15
(2) Calculate the corresponding tumor dose Di = di ∗ ri. If Di > 90, then reset Di to 90 and calculate
the corresponding di
(3) Calculate P(Ti= 1 | di,Mi)
(4) Calculate P(Ei= 1 | Di,Gi)
After doing this for all patients, we then calculated the average of P(Ti = 1) and P(Ei = 1) across
patients for each model and dose selection method.
3.4. Simulation results
Figure 4 shows utility-dose curves for example patients based on model 4. A comparison of the gray
and black lines shows how increasing 𝜃 results in selecting a smaller dose. Similarly, the optimal dose is
higher for patients with shallow dose-toxicity curves (TGF𝛼 < median) than for patients whose toxicity
increases more rapidly with dose.
The toxicity models that use the cytokine values in a continuous fashion sometimes ‘recommend’ very
high or very low dose values (e.g., d = 30 Gy). The rationale for the dose constraints in the simulation
is to avoid doses that clinicians would be uncomfortable prescribing, as well as to avoid extrapolating the
model predictions to dose values not seen in the dataset used to fit the models. To facilitate comparisons
of the different strategies/models and to avoid outcomes where one strategy had better efficacy but worse
toxicity than another strategy, we targeted the same level of toxicity with each so that they can be directly
compared with respect to efficacy.
Simulation results are given in Table I. Relative to the dose only model 1, use of models 2–4 resulted
in improved efficacy without increased toxicity. Although there is no statistical interaction of dose and
IL8 in model 2, the increase in 𝜋T (not logit(𝜋T )) varies with IL8. Thus, despite the earlier finding regard-
ing additive markers, model 2 results in improved efficacy. Intuitively, the reason why model 4 allows
improvement over model 1 is that the required reduction in d in the sensitive patients is just 2 Gy, while
the possible increase in d in the tolerant patients is 4 Gy (Figure 2). A general conclusion from the
results is that the ability to improve efficacy at a fixed toxicity is not closely correlated with AUC. For
example, the AUC of model 4 is just 0.76, considerably lower than the 0.83 for model 3. Yet both result
in approximately the same efficacy improvement because of the stronger marker * dose interaction in
the former.
Not surprisingly, for each of the models considered, the utility approach (even without using the effi-
cacy markers) outperforms the isotoxic approach. By allowing the probability of toxicity to vary across
subjects, the method ‘spends its toxicity’ in a manner that results in the largest possible efficacy. By
restricting every subject to be treated at a fixed 𝜋T , the isotoxic method exposes some patients to a dose
that, relative to a lower dose, may increase 𝜋T with only a small corresponding increase in 𝜋E, whereas
Figure 4. Utility values for example patients when r= (D/d) = 6
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 5330–5339
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other subjects that might experience relatively large increases in 𝜋E if 𝜋T were allowed to be higher,
have their dose limited. Conversely, in the utility-based approach, the only subjects exposed to higher
𝜋T are those with a larger than average increase in 𝜋E. In addition, we have shown that the utility func-
tion approach can target any desired level of toxicity for a population of patients through selection of an
appropriate value of 𝜃. Thus, prior to obtaining marker measurements, each patient’s expected probabil-
ity of toxicity and efficacy is equal to the population mean values (e.g., those given in Table I), which are
higher for efficacy and the same for toxicity. These are the relevant values to consider for an individual
patient deciding whether to pursue a dose selection scheme based on biomarkers. Incorporating the effi-
cacy marker allowed further gains in outcome as seen in Table I. Use of toxicity model 4 with the efficacy
marker allowed an increase in LPFS from 40% to 52% without increasing toxicity.
3.5. Correlation between toxicity and efficacy markers
Table II gives the relation between miRNA group and TGF𝛼 group for patients in our data. The two
variables are not highly correlated (odds ratio = 1.29, Fisher’s exact test p = 0.64).
Intuitively, a high degree of positive correlation would limit the potential gains of the marker-based
dose selection strategies discussed in this paper. The reason is that the same patients whose LPFS would
improve the most with high dose would also experience the largest increase in toxicity. Similarly, negative
correlation would seem to allow the largest improvements. Patients with high efficacy sensitivity but
low toxicity sensitivity would be natural candidates for high dose, whereas patients with low efficacy
sensitivity but high toxicity sensitivity would naturally receive lower dose. To investigate this empirically,
we repeated the simulation study after changingmiRNAgroup status for some patients. To induce positive
correlation, we took the 10 patients who were TGF𝛼 sensitive but miRNA not sensitive and changed their
miRNA group to sensitive. To keep the four marginal totals constant, we also took 10 of the 31 patients
who were TGF𝛼 not sensitive but miRNA sensitive and changed their miRNA group to not sensitive. We
repeated this in the opposite direction to induce negative correlation. To remove any effect of r(D∕d),
which varies between patients, we also set r = 5 for all patients. The results in Table III confirmed our
intuition with the negative correlation case allowing the greatest local control improvements.
4. Discussion
A natural test of the ability of these dose selection methods to improve outcomes would be a clinical
trial in which patients were randomized between marker-based and standard (fixed) dose selection. At
the same time, clinical use of these methods would ideally be based on validated models linking the
probabilities of toxicity and efficacy with dose and marker values. To build such models requires data
on patients treated over a range of dose values. If one were confident in the form of the models but
less confident regarding the actual parameter values, a Bayesian approach could be taken in which the
parameter values were updated throughout the trial based on accrued data. If the marker(s) were used to
Table II. Frequency table of patient’s toxicitymarker (TGF𝛼) group and efficacymarker
(miRNA signature) group.
TGF𝛼 < 3 (not sensitive) TGF𝛼 > 3 (sensitive)
miRNA group = 1 (not sensitive) 16 10 26
miRNA group = 2 (sensitive) 31 25 56
47 35
Table III. Effect of correlation between efficacy and toxicity markers on ability to improve local
control.
Local progression free survival at 2 years
Correlation between normal tissue and Utility without Utility With
tumor dose sensitivity Odds ratio Isotoxic efficacy markers efficacy markers
Observed in data 1.29 53 57 59
Positive Infinite 50 54 58
Negative 0 61 62 62
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identify a small number of groups of patients with distinct dose-toxicity or dose-efficacy relationships, a
more standard dose finding trial could be performed seeking to identify, for each marker defined group,
the dose that maximized the utility.
We have limited our attention to situations in which a patient’s initial dose is selected according to
the model and then possibly ‘scaled’ up or down mid-treatment. We have not considered the situation
in which patients are re-planned in such a way that the spatial distribution of dose is changed part way
through treatment. However, we expect that methods to use mid-treatment imaging to redistribute dose
to less sensitive normal tissue, or to more aggressive tumor regions, could be utilized ‘on top’ of the
proposed methods to allow greater improvements in outcome. Study of this is more difficult as it requires
the ability to generate new treatment plans, which requires patient images, dose maps and as a result is
much more computationally intensive. Nevertheless, such an approach seems likely to allow additional
gains over the scaling approach.
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